Paper16192597
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
D'Adamo DR and 8 others. J Clin Oncol, 2005. Cited by 202 papers, by iCite.
Cite this record
ConductScience Library. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. Papers, record 16192597. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16192597
- Disease
- soft tissue sarcoma233 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Sarcoma | Major topic |
| Adult | |
| Aged | |
| Antibodies, Monoclonal | |
| Antibodies, Monoclonal, Humanized | |
| Bevacizumab | |
| Doxorubicin | |
| Female | |
| Humans | |
| Infusions, Intravenous | |
| Injections, Intravenous | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| N01-CM17105 | NCI NIH HHS | United States | PubMed | PubMed | |
| P01 CA47179 | NCI NIH HHS | United States | P01CA047179 | PubMed and NIH | NIH RePORTER |
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00052390 | Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma | Results | ClinicalTrials.gov | |
| NCT00908219 | A Study of Bevacizumab to Prevent Malignant Ascites | Background | ClinicalTrials.gov | |
| NCT05366062 | ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab | Background | ClinicalTrials.gov |
Cited by72
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 202 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41132824 | Efficacy and safety of vascular-targeting agents in advanced soft tissue sarcoma: a systematic review and network meta-analysis. | Ther Adv Med Oncol | 2025 | https://conductscience.org/library/papers/41132824 | PubMed |
| 40481994 | Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/40481994 | PubMed |
| 40370992 | Simultaneous, Seconds-Resolved Doxorubicin Measurements in the Blood and Subcutaneous Interstitial Fluid Identify Quantitative Pharmacokinetic Relationships between the Two. | ACS Pharmacol Transl Sci | 2025 | https://conductscience.org/library/papers/40370992 | PubMed |
| 37568826 | Maintenance Chemotherapy for Patients with Rhabdomyosarcoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37568826 | PubMed |
| 37081717 | Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis. | Cancer Med | 2023 | https://conductscience.org/library/papers/37081717 | PubMed |
| 36497280 | Knockdown of NCOR2 Inhibits Cell Proliferation via BDNF/TrkB/ERK in NF1-Derived MPNSTs. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36497280 | PubMed |
| 36267741 | Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial. | Ann Transl Med | 2022 | https://conductscience.org/library/papers/36267741 | PubMed |
| 34094927 | Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review. | Front Oncol | 2021 | https://conductscience.org/library/papers/34094927 | PubMed |
| 33842348 | VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature. | Front Oncol | 2021 | https://conductscience.org/library/papers/33842348 | PubMed |
| 33574700 | Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas. | Cancer Manag Res | 2021 | https://conductscience.org/library/papers/33574700 | PubMed |
| 33330082 | Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. | Front Oncol | 2020 | https://conductscience.org/library/papers/33330082 | PubMed |
| 32974853 | Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study. | Invest New Drugs | 2021 | https://conductscience.org/library/papers/32974853 | PubMed |
| 32905214 | Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature. | Mol Clin Oncol | 2020 | https://conductscience.org/library/papers/32905214 | PubMed |
| 32824667 | Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab. | J Clin Med | 2020 | https://conductscience.org/library/papers/32824667 | PubMed |
| 32127798 | Integrative Clustering Reveals a Novel Subtype of Soft Tissue Sarcoma With Poor Prognosis. | Front Genet | 2020 | https://conductscience.org/library/papers/32127798 | PubMed |
| 32039918 | Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies. | J Clin Invest | 2020 | https://conductscience.org/library/papers/32039918 | PubMed |
| 30126857 | A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. | Oncologist | 2019 | https://conductscience.org/library/papers/30126857 | PubMed |
| 29890998 | Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. | J Transl Med | 2018 | https://conductscience.org/library/papers/29890998 | PubMed |
| 29527631 | Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study. | Invest New Drugs | 2018 | https://conductscience.org/library/papers/29527631 | PubMed |
| 29462961 | A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29462961 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1201583 | ChEMBL |
| DOXORUBICIN | CHEMBL53463 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL53463 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16192597
GET https://conductscience.org/api/papers/v1/16192597/cited_by?page=2